Salute e Benessere
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight
TIBSOVO (ivosidenib) is a small molecule developed by Servier, acts as an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is indicated for patients with a susceptible IDH1 mutation, which is identified through an FDA-approved test.
Currently, TIBSOVO is approved for the treatment of newly diagnosed acute myeloid leukemia (AML), relapsed or refractory AML, relapsed or refractory myelodysplastic syndromes (MDS), and locally advanced or metastatic cholangiocarcinoma.
According to Servier's pipeline, TIBSOVO is also being actively investigated for a range of additional indications, with key areas of exploration including solid tumors and hematological malignancies.
Learn more about TIBSOVO projected market size for AML, cholangiocarcinoma, and MDS @
The oncology market has experienced significant growth in recent years, driven by advances in cancer research, the development of targeted therapies, and the increasing global prevalence of cancer. As the second-leading cause of death worldwide, cancer continues to pose a major public health challenge, creating a substantial demand for innovative treatments. The market is marked by a shift toward personalized medicine, where therapies are tailored to an individual's genetic profile, allowing for more effective and less toxic treatments. Immunotherapies, such as checkpoint inhibitors, CAR-T cell therapies, and oncolytic virus therapies, are at the forefront of these advancements, offering new hope to patients with previously untreatable cancers.
Moreover, the oncology market is expanding due to the growing adoption of precision oncology and molecular diagnostics, which enable earlier and more accurate detection of cancer. This has led to increased investments in research and development, especially in areas like liquid biopsies, companion diagnostics, and next-generation sequencing. The demand for more effective and accessible cancer treatments is fueling innovation in both the pharmaceutical and biotechnology sectors, with numerous new drugs and therapies entering clinical trials and moving toward commercialization. As a result, the oncology market is poised to continue growing, with significant opportunities for breakthrough therapies in immuno-oncology, targeted treatments, and gene therapies.
DelveInsight has expertise in the oncology market with an experienced team handling the oncology domain proficiently. DelveInsight has released a series of epidemiology-based market reports on . These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ].
Gain deeper insights into these diseases with a customized report tailored to your needs. —our experts are ready to assist you!
TIBSOVO faces significant competition in the newly diagnosed AML market from several alternative treatments. Oral therapies like , which inhibits BCL-2, and , which targets the hedgehog pathway, present strong contenders. Additionally, emerging therapies such as , another BCL-2 inhibitor, and , a kinase inhibitor, are expected to further challenge TIBSOVO in the newly diagnosed AML space.
In the R/R AML market, TIBSOVO competes with several therapies, including , , and others. Emerging therapies such as are also expected to compete with TIBSOVO upon their approval. Ziftomenib, a small molecule developed by Kura Oncology, is currently in Phase I/II trials.
In the relapsed/refractory (R/R) MDS market, TIBSOVO faces competition from therapies such as , an IV injection that inhibits oligonucleotide telomerase, and , a subcutaneous injection, among other treatment options.
In the metastatic cholangiocarcinoma market, TIBSOVO faces relatively less competition, as there are few approved therapies. One such competitor is , a kinase inhibitor that was approved in the US in 2020 and in Europe in 2021. Whereas, Tyra Biosciences' TYRA-200, an FGFR1/2/3 inhibitor, is in phase I stage of development that might be a threat to TIBSOVO one approved.
To know more about the number of competing drugs in development, visit @
TIBSOVO is a drug owned by Servier Pharmaceuticals. Currently, it is protected by 10 Orange book-listed patents filed from 2018 to 2023, out of which none have expired yet. It is also protected by ODE exclusivity for various indications.
Discover how TIBSOVO is shaping the blood cancer treatment landscape @
In recent years, the therapeutic landscape has undergone significant changes, with promising approaches including
. One such treatment,
, works by inducing the bone marrow to develop normal blood cells, helping to reduce the frequency of blood transfusions.
Investment in the has surged, contributing to a rich pipeline and forecasting promising opportunities in the treatment markets for AML and cholangiocarcinomas. Therapies like TIBSOVO have the potential to capture market attention due to their .
As continues to rise globally, the pharmaceutical market is expected to expand, providing greater opportunities for the development and distribution of new treatments.
Despite progress in cancer treatment, remain in understanding the full process that governs carcinogenesis and resistance to treatments, particularly in cancers like acute myeloid leukemia (AML). This highlights the to address these challenges. Additionally, the for patients with the IDH1 mutation restricts the targeted patient pool, posing a challenge for therapies like TIBSOVO to achieve their expected market share.
The , such as KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), and the combination of Azacitidine + Venetoclax, further intensifies the pressure on TIBSOVO. Moreover, the and during disease recurrence presents significant hurdles to the effective development of translational research, potentially slowing progress in optimizing treatments.
Dive deeper to get more insight into TIBSOVO's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AML companies including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key R/R AML companies including among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key MDS companies such as among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cholangiocarcinoma companies such as among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/tibsovos-continued-success-solidifies-its-position-as-a-leader-in-idh1-mutant-space--delveinsight-302422944.html